MabSpace Biosciences Co., Ltd., a Suzhou, China-based company focused on the discovery and development of antibody-based therapeutics, completed a $15m Series A financing.
Lilly Asia Ventures was the sole investor for the round.
Led by Dr. Xueming Qian, Founder, Chairman and CEO, MabSpace specializes in the discovery and early-development of antibody-based therapeutics, with a focus on developing antibody therapeutics for cancer treatment.
The company, which has a fully-integrated antibody discovery and development facility in Biobay, Suzhou Industrial Park, intends to use the funds to advance its pipeline of therapeutic antibody programs into clinical studies, and enable expanded discovery of novel antibodies aimed at various components of tumor microenvironment to enhance responses of tumors that may be less likely to respond to T cell checkpoint monotherapy.
FinSMEs
29/10/2015